EPIDEMIOLOGY OF PULMONARY TUBERCULOSIS

LEARNIN G OBJECTIVES

- State the diagnostic criteria of pulmonary tuberculosis
- Describe trend & state reasons for resurgence of pulmonary tuberculosis
- List population subgroups at risk of pulmonary tuberculosis
- Draw the cycle of infection of pulmonary tuberculosis
- Outline the procedures of diagnosis of pulmonary tuberculosis with emphasis on the limitation of each procedure
- Describe measures for the prevention and control of pulmonary tuberculosis
- Describe the Directly Observed Therapy short course for the treatment of pulmonary tuberculosis

PERFORMANCE OBJECTIVE

To decide on the best measure(s) for the prevention and control of pulmonary tuberculosis and to prevent its spread to susceptible population

Respiratory tract infection

Caused by M. Tuberculosis

Suspected cases present with

Cough & expectoration for 3 weeks

Low grade fever

Night sweating

Loss of weight

SMEAR POSITIVE

SMEAR NEGATIVE

- 2 Positive sputum smears OR,
- 1 Positive sputum smear
- + positive radiology OR,

- 1 Positive sputum smear
- + positive culture

- 3 Negative sputum smears
- + Suggestive symptoms
- + Positive radiology
- + Decision to treat as TB

OR,

Culture positive but negative sputum smear

INFECTION

Primary First exposure


Post primary Reactivation/re-infection

DISEASE

Active tuberculosis Disease process


Latent tuberculosis No disease yet

Estimated TB incidence rates, 2013



Global Tuberculosis Report – WHO, 2014

Percentage of new TB cases with MDR-TBa



^a Figures are based on the most recent year for which data have been reported, which varies among countries.

PULMONARY TUBERCULOSIS IN SAUDI ARABIA

64,345 reported cases; 48% non-Saudis for 2000 – 2013

Annual incidence rate (2013)

- Between 14 to 17 per 100,000 populations
- Between 8.6 and 12.2 per 100,000 Saudi population

RESSUREGENCE OF TUBERCULOSIS

- Deterioration of the living conditions
- Appearance of strains of M. tuberculosis resistant to anti-tuberculosis drugs.
- HIV/AIDS pandemic

Resurging diseases are Infectious diseases which its incidence has increased in the past two decades or threaten to increase in the near future after a considerable period of decline.

Social factors: Unfavorable social conditions

Pre-pathogenic conditions: HIV/AIDS, diabetes

Occupation: Exposure & working conditions

Habit: Smoking

PROGRESS

Annual slow decline in the rates of tuberculosis

 An estimated of 37 million lives saved between 2000 and 2013 as a result of effective diagnosis and treatment.

CYCLE OF INFECTION OF PULMONARY TUBERCULOSIS




Susceptible host:

Low standard of livings, malnutrition, alcoholism, HIV/AIDS



Agent:
Mycobacterium
tuberculosis



Incubation period=4-12 weeks





Transmission:


Contact: Direct, indirect& droplet

Air borne: droplet nuclei & dust transmission



Reservoir

Man in the form of a case



contaminated articles, dust

DIAGNOSIS OF TUBERCULOSIS

Non specific symptoms and signs (mimic chest infection)

Delay consultation + Delay diagnosis

DIAGNOSIS OF PULMONARY TUBERCULOSIS


Tuberculin skin test (Mantoux technique)

Chest radiography

Microscopic examination of sputum specimen

Culture of sputum specimen

TUBERCULIN SKIN TEST



TUBERCULIN SKIN TEST

Report induration size in mm

Induration = Previous exposure to M. protein


Size

10 + mm = positive

5 - <10 mm = positive in immune compromised

≥ 15 mm = suggestive of infection rather than BCG





TUBERCULIN TESTING IN MANAGING CONTACTS

CHEST RADIOGRAPHY

Chest radiography findings

Enlarged mediastinal LN

Consolidation (area of opacity)

Cavitations (dark area)


Negative (not uncommon)

SPUTUM SMEAR & CULTURE




Collection







Culture



PREVENTION AND CONTROL OF RIS

PREVENTION & CONTROL OF RIS

Minimize exposure

- Isolation of case
 (respiratory precautions)
- Concurrent disinfection (patients' items)
- Ventilation & exposure to sunlight
- Cleaning floor with disinfectant

Control transmission

Protection of susceptible

- BCG vaccine:
 Live attenuated vaccine, 0.1 ml
 IM injection in the left deltoid within 40 days of birth
- Improve nutrition status

Increase host resistance

Identification and treatment

Anti-tuberculosis drugs

Eliminate reservoir

DIRECTLY OBSERVED THERAPY SHORT COURSE (DOTS)

2 months

4 months

Initial phase

(2 HRZE)
Isoniazid (H)
Rifampicin (R)
Pyrazinamide (Z)
Ethambutol (E)

Maintenance phase

(4 HR) daily or (4 HR) $_{3 \text{ (three times per week)}}$ Isoniazid (H) Rifampicin (R)

First line medications

DIRECTLY OBSERVED THERAPY SHORT COURSE (DOTS)

Strategy to improve compliance

Fixed Dose Combination therapy (FDC) - ALL IN ONE tablet

